Patient characteristics
| Patient group/UPN no. . | Age, y/sex . | NHL type and stage . | Previous treatment, response/duration . | Sites of disease at vaccination (cm*) . | Clinical response, time to progression . | Postvaccination therapy . | Current status, survival after the last vaccination . |
|---|---|---|---|---|---|---|---|
| Clinically responding patients | |||||||
| 12 | 65/M | LP, stage IA | 6 CVP (CR/36 mo) | Periaortic LNs (1.8); BM and PB | CR | No additional tx | CR, +49 mo |
| 13 | 72/F | FL grade I, stage IIA | 6 CVP (PR/16 mo); 4 rituximab (CR/24 mo) | Mediastinal, axillary and supraclavicular LNs (2) | CR | No additional tx | CR, +46 mo |
| 14 | 52/F | FL grade IIIa, stage IVA | 6 R-MegaCEOP (PR/10 mo); HDS (CR/6 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (2.5) | CR | No additional tx | CR, +45 mo |
| 1 | 49/F | LP, stage IVA | 6 CVP (CR/48 mo); 8 rituximab (PR/72 mo) | Cervical, axillary, mediastinal, periaortic, peri-iliac LNs (2.5); BM | PR, 47 mo | No additional tx | PD, +63 mo |
| 5 | 52/M | FL grade I, stage IVA | 6 CVP (CR/24 mo); 4 rituximab (PR/15 mo) | Cervical, periaortic and peri-iliac LNs (2.5); BM | PR, 12 mo | HDS autoBMT | PR, +56 mo |
| 6 | 45/M | FL grade II, stage IVA | 6 R-CEOP (CR/12 mo); 4 rituximab (PR/8 mo); HDS (CR/12 mo) | Cervical, axillary, mediastinal, periaortic and inguinal LNs (2.5) | PR, 7 mo | DHAP | Died, 22 mo |
| Patients with stable disease | |||||||
| 2 | 60/M | LP, stage IVA | 6 CVP (PR/36 mo); 6 rituximab (CR/48 mo) | Cervical, axillary and mediastinal LNs (3); spleen; BM and PB | SD | No additional tx | SD, +62 mo |
| 4 | 51/M | FL grade II, stage IA | 4 rituximab (CR/24 mo); RT 30 Gy (CR/24 mo) | Inguinal and peri-iliac LNs (2.5) | SD | No additional tx | SD, +60 mo |
| 9 | 63/M | LP, stage IVA | 8 rituximab (PR/16 mo); 4 CVP (PR/18 mo); 4 R-CHOP (SD/32 mo) | BM (massive) and PB | SD | No additional tx | SD, +51 mo |
| 10 | 54/M | FL grade I, stage IVA | 8 R-CVP (CR/36 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (5); BM | SD | No additional tx | SD, +50 mo |
| 11 | 72/M | FL grade II, stage IVB | 18 mo leukeran (CR/84 mo) | Cervical, axillary, mediastinal, periaortic and inguinal LNs (4); BM | SD, 10 mo | R-CHOP | CR, +50 mo |
| 16 | 55/F | FL grade I, stage IVA | 6 CVP (CR/24 mo) | Axillary, cervical, mediastinal and periaortic LNs (3); BM and PB | SD | No additional tx | SD, +37 mo |
| 17 | 65/M | LP, stage IIIA | 8 CVP (CR/98 mo) | Cervical, axillary, mediastinal and periaortic LNs (3); spleen; BM | SD, 10 mo | HDS autoBMT | CR +34 mo |
| 18 | 62/F | FL grade I, stage IIIA | 6 R-CVP (CR/36 mo); 4 rituximab (CR/26 mo) | Axillary, periaortic and peri-iliac LNs (4) | SD | No additional tx | SD, +34 mo |
| Patients with progressive disease | |||||||
| 3 | 60/M | FL grade II, stage IVA | 8 CHOP (PR/16 mo) 6 rituximab (PR/8 mo) | Axillary, mediastinal, periaortic, inguinal LNs (3); spleen | PD, 1 mo | HDS autoBMT | CR +60 mo |
| 7 | 50/M | FL grade I, stage IVA | 6 CHOP (PR/12 mo); 4 rituximab (PR/6 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (6); BM | PD, 1 mo | HDS autoBMT | CR, +51 mo |
| 8 | 56/M | FL grade II, stage IA | 3 CHOP-bleo/3 CVP (RC/16 mo); HDS (CR/24 mo); 8 rituximab (CR/6 mo) | Periaortic, peri-iliac and inguinal LNs (3.2) | PD, 1 mo | AlloBMT | CR, +50 mo |
| 15 | 72/M | LP, stage IA | 3 CHOP (PR/8 mo); splenectomy + RT (PR/12 mo); 12 mo leukeran (PR/7 mo); HDS (CR/12 mo); 4 rituximab (PD/na) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (6.5); BM and PB | PD, 1 mo | DHAP | Died, 7 mo |
| Patient group/UPN no. . | Age, y/sex . | NHL type and stage . | Previous treatment, response/duration . | Sites of disease at vaccination (cm*) . | Clinical response, time to progression . | Postvaccination therapy . | Current status, survival after the last vaccination . |
|---|---|---|---|---|---|---|---|
| Clinically responding patients | |||||||
| 12 | 65/M | LP, stage IA | 6 CVP (CR/36 mo) | Periaortic LNs (1.8); BM and PB | CR | No additional tx | CR, +49 mo |
| 13 | 72/F | FL grade I, stage IIA | 6 CVP (PR/16 mo); 4 rituximab (CR/24 mo) | Mediastinal, axillary and supraclavicular LNs (2) | CR | No additional tx | CR, +46 mo |
| 14 | 52/F | FL grade IIIa, stage IVA | 6 R-MegaCEOP (PR/10 mo); HDS (CR/6 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (2.5) | CR | No additional tx | CR, +45 mo |
| 1 | 49/F | LP, stage IVA | 6 CVP (CR/48 mo); 8 rituximab (PR/72 mo) | Cervical, axillary, mediastinal, periaortic, peri-iliac LNs (2.5); BM | PR, 47 mo | No additional tx | PD, +63 mo |
| 5 | 52/M | FL grade I, stage IVA | 6 CVP (CR/24 mo); 4 rituximab (PR/15 mo) | Cervical, periaortic and peri-iliac LNs (2.5); BM | PR, 12 mo | HDS autoBMT | PR, +56 mo |
| 6 | 45/M | FL grade II, stage IVA | 6 R-CEOP (CR/12 mo); 4 rituximab (PR/8 mo); HDS (CR/12 mo) | Cervical, axillary, mediastinal, periaortic and inguinal LNs (2.5) | PR, 7 mo | DHAP | Died, 22 mo |
| Patients with stable disease | |||||||
| 2 | 60/M | LP, stage IVA | 6 CVP (PR/36 mo); 6 rituximab (CR/48 mo) | Cervical, axillary and mediastinal LNs (3); spleen; BM and PB | SD | No additional tx | SD, +62 mo |
| 4 | 51/M | FL grade II, stage IA | 4 rituximab (CR/24 mo); RT 30 Gy (CR/24 mo) | Inguinal and peri-iliac LNs (2.5) | SD | No additional tx | SD, +60 mo |
| 9 | 63/M | LP, stage IVA | 8 rituximab (PR/16 mo); 4 CVP (PR/18 mo); 4 R-CHOP (SD/32 mo) | BM (massive) and PB | SD | No additional tx | SD, +51 mo |
| 10 | 54/M | FL grade I, stage IVA | 8 R-CVP (CR/36 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (5); BM | SD | No additional tx | SD, +50 mo |
| 11 | 72/M | FL grade II, stage IVB | 18 mo leukeran (CR/84 mo) | Cervical, axillary, mediastinal, periaortic and inguinal LNs (4); BM | SD, 10 mo | R-CHOP | CR, +50 mo |
| 16 | 55/F | FL grade I, stage IVA | 6 CVP (CR/24 mo) | Axillary, cervical, mediastinal and periaortic LNs (3); BM and PB | SD | No additional tx | SD, +37 mo |
| 17 | 65/M | LP, stage IIIA | 8 CVP (CR/98 mo) | Cervical, axillary, mediastinal and periaortic LNs (3); spleen; BM | SD, 10 mo | HDS autoBMT | CR +34 mo |
| 18 | 62/F | FL grade I, stage IIIA | 6 R-CVP (CR/36 mo); 4 rituximab (CR/26 mo) | Axillary, periaortic and peri-iliac LNs (4) | SD | No additional tx | SD, +34 mo |
| Patients with progressive disease | |||||||
| 3 | 60/M | FL grade II, stage IVA | 8 CHOP (PR/16 mo) 6 rituximab (PR/8 mo) | Axillary, mediastinal, periaortic, inguinal LNs (3); spleen | PD, 1 mo | HDS autoBMT | CR +60 mo |
| 7 | 50/M | FL grade I, stage IVA | 6 CHOP (PR/12 mo); 4 rituximab (PR/6 mo) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (6); BM | PD, 1 mo | HDS autoBMT | CR, +51 mo |
| 8 | 56/M | FL grade II, stage IA | 3 CHOP-bleo/3 CVP (RC/16 mo); HDS (CR/24 mo); 8 rituximab (CR/6 mo) | Periaortic, peri-iliac and inguinal LNs (3.2) | PD, 1 mo | AlloBMT | CR, +50 mo |
| 15 | 72/M | LP, stage IA | 3 CHOP (PR/8 mo); splenectomy + RT (PR/12 mo); 12 mo leukeran (PR/7 mo); HDS (CR/12 mo); 4 rituximab (PD/na) | Cervical, axillary, mediastinal, periaortic and parailiac LNs (6.5); BM and PB | PD, 1 mo | DHAP | Died, 7 mo |
UPN indicates unique progressive number; LP, lymphoplasmocitoid non-Hodgkin lymphoma; FL, follicular lymphoma; Cheson criteria (xx) have been used to define the response to vaccination: complete remission (CR), disappearance of all evidence of disease; partial response (PR): regression of 50% or more of measurable disease and no new sites; stable disease (SD): failure to attain CR/PR or PD; progressive disease (PD): any new lesion or increase by 50% or more of previously involved sites from nadir; CVP, cyclophosphamide, vincristine and prednisone; R-CVP, rituximab plus CVP; CHOP, cyclophosphamide, adryamicin, vincristine and prednisone; R-CHOP, rituximab plus CHOP; RT, radiotherapy; CEOP, cyclophosphamide, epiadryamicin, vincristine, and prednisone; R-CEOP, rituximab plus CEOP; HDS, high-dose sequential chemotherapy; autoBMT, autologous bone marrow transplantation; alloBMT, allogeneic bone marrow transplantation; LNs, lymph nodes; BM, bone marrow; PB, peripheral blood; DHAP, desametasone, cis-platinum, aracytin; and tx, therapy.
Maximum diameter of the largest lesion.